drugset / Trial / NCT00938730

A Study Evaluating Safety and Tolerability of YM150 Compared to Warfarin in Subjects With Atrial Fibrillation

NCT00938730

Phase 2 Completed 1280 enrolled Astellas Pharma Inc
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to investigate the optimal daily dose and dose regimen of YM150 in subjects with non-valvular atrial fibrillation (NVAF), primarily based on safety and tolerability data.

Timeline

Start
2009-06
Primary completion
2010-09
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Warfarin Small molecule Oral
Subject darexaban Small molecule Oral

Indications